Shanghai Kechow Pharma, Inc.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2014-06-18
- Employees
- 51
- Market Cap
- -
- Website
- http://www.kechowpharma.com
A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Shanghai Kechow Pharma, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT03781219
- Locations
- 🇨🇳
First Affiliated Hospital, Medicine School of Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇨🇳Henan Province Oncology Hospital, Zhengzhou, Henan, China
© Copyright 2024. All Rights Reserved by MedPath